57668-34-5

Upstream product

• 621-54-5 3-(3-hydroxyphenyl)-propanoic acid 
• 100-39-0 benzyl bromide 
• 495399-41-2 methyl 3-(3-benzyloxyphenyl)propenoate 
• 14755-02-3 3-hydroxy-trans-cinnamic acid 
• 34708-60-6 3-(3-hydroxy-phenyl)propionic acid ethyl ester 
• 1352791-76-4 tert-butyl 3-[3-(benzyloxy)phenyl]propanoate 
• 1700-31-8 3-benzyloxybenzyl bromide 
• 149506-38-7 benzyl 3-(3-(benzyloxy)phenyl)propanoate 
• 96251-92-2 (E)-3-(3-hydroxyphenyl)acrylic acid ethyl ester 
• 100-83-4 meta-hydroxybenzaldehyde 
• 1700-37-4 3-Benzyloxybenzaldehyde 
• 476458-89-6 3-(3-benzyloxy-phenyl)-propionic acid methyl ester 
• 100-44-7 benzyl chloride 

Downstream Products

• 121484-76-2 3-(3-benzyloxy-phenyl)-propionyl chloride 
• 222556-16-3 (4S)-4-benzyl-3-[3-{3-(benzyloxy)phenyl}propanoyl]oxazolidin-2-one 
• 374938-41-7 N-(1S,2R-indanyl-2-ol)-3-(3-benzyloxy-phenyl)-propanamide 
• 121484-78-4 5-(2-(3-(3-hydroxyphenyl)propamido)phenyl)-10,15,20-triphenylporphyrin 
• 121484-77-3 5-(2-(3-(3-benzyloxyphenyl)propamido)phenyl)-10,15,20-triphenylporphyrin 
• 1165946-24-6 3-{3-[(phenylmethyl)oxy]phenyl}propanamide 
• 1352791-75-3 (3R)-2-[3-(benzyloxy)benzyl]-4-tert-butoxy-4-oxobutanoic acid 
• 1352791-78-6 tert-butyl (3R)-3-[3-(benzyloxy)benzyl]-4-[(1S,2R,3R,3aS,7aR)-2-hydroxy-3-{(S)-N-methylphenylsulfonimidoyl}octahydro-1H-inden-1-ylamino]-4-oxobutanoate 
• 1352791-72-0 (2R)-N₄-benzyloxy-2-[3-(benzyloxy)benzyl]-N₁-[(1S,2R,3R,3aS,7aR)-2-hydroxy-3-{(S)-N-methylphenylsulfonimidoyl}octahydro-1H-inden-1-yl]succinamide 
• 946136-58-9 C₂₂H₂₇NO₂ 
• 120363-35-1 (S)-2-(3-{4-[3-(2-Amino-ethyl)-phenoxy]-phenyl}-propionylamino)-3-(4-hydroxy-phenyl)-propionic acid pentafluorophenyl ester; hydrochloride 
• 120363-43-1 3-[4-(3-{2-[(S)-2-Amino-3-(4-hydroxy-phenyl)-propionylamino]-ethyl}-phenoxy)-phenyl]-propionic acid; hydrochloride 
• 120363-34-0 (S)-2-(3-{4-[3-(2-Amino-ethyl)-phenoxy]-phenyl}-propionylamino)-3-(4-hydroxy-phenyl)-propionic acid; hydrochloride 
• 129150-82-9 3-[4-(3-{2-[(S)-2-tert-Butoxycarbonylamino-3-(4-hydroxy-phenyl)-propionylamino]-ethyl}-phenoxy)-phenyl]-propionic acid methyl ester 

Relevant academic research and scientific papers

MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS

The compounds of the present invention are represented by the following compounds having Formula I and Formula (I'): where the substituents R1, R2, R2', R3, R4, R5, R', R", X, Y, and Z are as defined herein and where the substituents R1, R2, R3, R4, R5, R', R", X, Y, and Z are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

Asymmetric synthesis of functionalized bicyclic β-amino alcohols by cascade hydrometallation-cyclization-reduction of glycinyl-substituted alkenylsulfoximines - Application to the synthesis of an aggrecanase inhibitor mimic

The treatment of exocyclic alkenylsulfoximines, which carry an α-glycinyl group at the allylic position, with HAliBu2 caused cascade hydroalumination-cyclization-reduction and delivered the corresponding enantio- and diastereopure sulfoximine-substituted bicyclic β-amino alcohols with a bicyclo[3.3.0]octane and bicyclo[4.3.0]nonane skeleton in high yields. Three consecutive stereogenic C atoms of the bicyclic β-amino alcohols were generated in the cascade reactions with high diastereoselectivities. Application of the hydroalumination-cyclization- reduction to a ketal-substituted six-membered exocyclic alkenylsulfoximine afforded the corresponding sulfoximine-substituted β-amino alcohol with aketal-functionalized bicyclo[4.3.0]nonane skeleton. Reduction of a sulfoximine-substituted β-amino alcohol gave the parent β-amino alcohol, whereas its oxidative deamination afforded the corresponding sulfonyl-substituted β-amino alcohol. The treatment of a sulfoximine-substituted β-amino alcohol with chloro- and iodoformates stereoselectively furnished the corresponding chloro- and iodo-substituted β-amino alcohols. Finally, the feasibility of a dehydration and elimination of sulfoximine-substituted β-amino alcohols with formation of the corresponding amino-substituted alkenylsulfoximine and allylic amine was demonstrated. An enantio- and diastereopure protected aggrecanase inhibitor mimic was synthesized in high yield starting from the sulfoximine-substituted bicyclic β-amino alcohol with a bicyclo[4.3.0]nonane skeleton and (R)-2-(3-benzyloxy)benzyl-4-tert-butoxy-4-oxobutanoic acid. Coupling of both building blocks gave the corresponding succinamide, the tert-butoxycarbonyl group of which was converted into the corresponding O-benzyl-hydroxycarbamoyl group. The treatment of glycinyl-substituted alkenylsulfoximines with HAliBu2 gave from a cascade hydroalumination-cyclization-reduction sulfoximine-substituted bicyclic β-amino alcohol in high yields and diastereoselectivities. Coupling of a bicyclic β-amino alcohol with a chiral succinic acid derivative afforded a protected aggrecanase inhibitor mimic.

Macrocyclic BACE inhibitors: Optimization of a micromolar hit to nanomolar leads

We have identified macrocyclic inhibitors of the aspartic protease BACE, implicated in the etiology of Alzheimer's disease. An X-ray structure of screening hit 1 in the BACE active site revealed a hairpin conformation suggesting that constrained macrocycl

1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES

The present invention relates to novel oxadiazole derivatives of formula (I) or a pharmaceutically acceptable salt thereof thereof. Compounds of formula (I) and their pharmaceutically acceptable salts are of use in the treatment of conditions or disorders

Discovery of azetidinone acids as conformationally-constrained dual PPARα/γ agonists

A novel class of azetidinone acid-derived dual PPARα/γ agonists has been synthesized for the treatment of diabetes and dyslipidemia. The preferred stereochemistry in this series for binding and functional agonist activity against both PPARα and PPARγ receptors was shown to be 3S,4S. Synthesis, in vitro and in vivo activities of compounds in this series are described. A high-yielding method for N-arylation of azetidinone esters is also described.

MACROCYCLE DERIVATIVES USEFUL AS INHIBITORS OF beta-SECRETASE (BACE)

The present invention is directed to macrocycle derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD) and related disorders. The compounds of the invention are inhibitors of β-secretase, also known as β-site cleaving enzyme and BACE, BACE1, Asp2 and memapsin2.

INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME

Compounds of formula (I) are hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp) inhibitors, and are useful in therapeutic and prophylactic treatment of persons infected with hepatitis C virus.

Development of tripeptidyl farnesyltransferase inhibitors.

The first example of tripeptide inhibitors of farnesyltransferase with sub-micromolar inhibition activity was developed based on the fact that CVFM is not a substrate for farnesyltransferase.

A synthesis of the C1-N12 tripeptide fragment of sanglifehrin A

The synthesis of the C1-N12 tripeptide of the novel immunosuppressant sanglifehrin A is described. Evans oxazolidinone methodology was used to install the C8 stereocentre of the meta-tyrosine sub-unit.

Total Synthesis of L,L-Isodityrosine and Isodityrosine-Derived Agents: K-13, OF4949-III, and OF4949-IV

Full details of the development of reaction conditions for implementation of an activated Ullmann condensation reaction that may be conducted without amino acid racemization and that have proven suitable for incorporation of the selectively protected cate